Clinical trials in Luebeck – page 13

359 clinical trials in Luebeck, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Luebeck at a glance

359

clinical trials

Research sites1

Quick filters

359 trials in Luebeck

Open in trial search

Glomerulonephritis rapidly progressive

Recruiting

Study on the Safety and Tolerability of Lixudebart and Rituximab for Patients with Rapidly Progressive Glomerulonephritis Due to ANCA-Associated Vasculitis

Registered drug

Study on the Safety and Tolerability of Lixudebart and Rituximab for Patients with Rapidly Progressive Glomerulonephritis Due to ANCA-Associated Vasculitis

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Lixudebart
Sponsor:Alentis Therapeutics AG

Contact Research Centre

Pancreatic carcinoma

Recruiting

Study on Treatment Options for Patients with Oligometastatic Pancreatic Cancer: Comparing Oxaliplatin, Fluorouracil, Folinic Acid, and Drug Combination

Registered drugNo placebo

Study on Treatment Options for Patients with Oligometastatic Pancreatic Cancer: Comparing Oxaliplatin, Fluorouracil, Folinic Acid, and Drug Combination

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Fluorouracil
Sponsor:Universitaetsmedizin Goettingen

Contact Research Centre

Chronic kidney disease

Recruiting

Study on Dapagliflozin and Lifestyle Changes for Patients with Early Chronic Kidney Disease and Prediabetes

Registered drug

Study on Dapagliflozin and Lifestyle Changes for Patients with Early Chronic Kidney Disease and Prediabetes

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Dapagliflozin
Sponsor:Universitaetsklinikum Tuebingen AöR

Contact Research Centre

Plasma cell myeloma refractory

Recruiting

Study of isatuximab, belumosudil and dexamethasone combination treatment for patients with relapsed or refractory multiple myeloma

Registered drugNo placebo

Study of isatuximab, belumosudil and dexamethasone combination treatment for patients with relapsed or refractory multiple myeloma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Belumosudil Mesilate
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Plasma cell myeloma refractory

Recruiting

Study of isatuximab, pomalidomide and dexamethasone combination for patients with relapsed or refractory multiple myeloma

Registered drugNo placebo

Study of isatuximab, pomalidomide and dexamethasone combination for patients with relapsed or refractory multiple myeloma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Dexamethasone
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Plasma cell myeloma refractory

Recruiting

Study of isatuximab, evorpacept and dexamethasone combination therapy for patients with relapsed or refractory multiple myeloma

Registered drugNo placebo

Study of isatuximab, evorpacept and dexamethasone combination therapy for patients with relapsed or refractory multiple myeloma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Dexamethasone
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study on Decitabine, Venetoclax, and Tretinoin for Patients with Acute Myeloid Leukemia Who Cannot Have Induction Chemotherapy

Registered drug

Study on Decitabine, Venetoclax, and Tretinoin for Patients with Acute Myeloid Leukemia Who Cannot Have Induction Chemotherapy

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Placebo
Sponsor:Medical Center - University Of Freiburg

Contact Research Centre

Breast cancer+2

Recruiting

Study Comparing Trastuzumab Deruxtecan with a Drug Combination for Patients with HER2+ Early Breast Cancer

Registered drugNo placebo

Study Comparing Trastuzumab Deruxtecan with a Drug Combination for Patients with HER2+ Early Breast Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Trastuzumab Deruxtecan
Sponsor:WSG Women's Cancer Study Group GmbH

Contact Research Centre

Adenocarcinoma gastric+1

Recruiting

Study on the Effectiveness of Oxaliplatin, Docetaxel, and Fluorouracil in Patients with Resectable Gastric and Gastroesophageal Junction Cancer

Registered drugNo placebo

Study on the Effectiveness of Oxaliplatin, Docetaxel, and Fluorouracil in Patients with Resectable Gastric and Gastroesophageal Junction Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Krankenhaus Nordwest GmbH

Contact Research Centre

Dermatitis atopic

Not yet recruiting

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

Registered drug

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

Registered drug

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Lebrikizumab
Sponsor:Almirall S.A.

Contact Research Centre

Obesity+2

Not yet recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational

Germany

Participants:18–64 years
Sponsor:Novo Nordisk A/S

Contact Research Centre

Dermatitis atopic

Not yet recruiting

A Phase 2b Study Evaluating the Efficacy and Safety of ENV-294 in Adults with Moderate-to-Severe Atopic Dermatitis

Investigational

A Phase 2b Study Evaluating the Efficacy and Safety of ENV-294 in Adults with Moderate-to-Severe Atopic Dermatitis

Investigational

Germany

Participants:18–64 years · 65+ years

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Luebeck

What the registry says about research in the country

01 Oncology Research

Advanced clinical trials focusing on various cancer types, including metastatic prostate cancer, breast cancer, and non-small cell lung cancer. Studies evaluate novel therapeutic approaches and combination treatments.

Breast Cancer Treatments
Prostate Cancer Therapies
Lung Cancer Innovations

Investigating groundbreaking treatments targeting specific genetic markers and exploring immunotherapy combinations.

02 Neurological Disorders

Innovative research addressing acute cerebral ischemic stroke and amyotrophic lateral sclerosis (ALS). Studies focus on improving patient outcomes and testing new therapeutic agents.

Stroke Treatment
ALS Management
Neurological Recovery

Evaluating novel compounds to enhance neurological function and patient quality of life.

03 Autoimmune Conditions

Research into VEXAS syndrome and systemic autoimmune rheumatic diseases. Studies examine innovative treatments for complex inflammatory conditions.

Rheumatic Disease Management
Inflammatory Disorders
Lung Disease Complications

Testing new therapeutic approaches for rare and challenging autoimmune conditions.

04 Dermatological Studies

Clinical trials investigating treatments for hidradenitis suppurativa and atopic dermatitis. Research focuses on innovative therapies for chronic skin conditions.

Chronic Skin Conditions
Inflammatory Skin Disorders
Novel Treatment Approaches

Evaluating new therapeutic options for improving patient outcomes in persistent skin conditions.

Back to Germany All countries